ACTRN12606000163505已完成2 期
ATTAX: A randomised phase II study evaluating tumour response rates of a weekly schedule of docetaxel with cisplatin and 5-FU (wTCF) or with Capecitabine (wTX) in advanced oesophago-gastric cancer.
Australasian Gastro-Intestinal Trials Group A(AGITG)0 个研究点目标入组 100 人开始时间: 2006年5月9日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Histological diagnosis of metastatic or locally recurrent oesophago-gastric cancer (squamous cell, adenocarcinoma or undifferentiated carcinoma)-Any primary oesophago-gastric site (oesophagus, oesophago-gastric junction (OGJ) or stomach)-Unidimensional measurable disease as assessed by CT scan (RECIST criteria)- No prior radiation except for; Adjuvant radiation (radiation alone or chemo-radiation allowed) which must have been completed >12 months ago. For patients who have received adjuvant radiotherapy, the site(s) of measurable disease should include at least one which was not encompassed by the radiation field(s) unless this site has demonstrated clear progression.Palliative radiotherapy provided there was no concurrent chemotherapy administered, all radiation toxicities have resolved to grade 1 or less and at least 14d has elapsed from the last dose of radiotherapy until the start of chemotherapy in ATTAX. For patients who have received palliative radiotherapy, the site(s) of measurable disease should include at least one which was not encompassed by the radiation field(s)-No prior chemotherapy agents, except adjuvant chemotherapy > 12 months ago.
排除标准
- •Metastatic disease of the central nervous system.
研究者
相似试验
终止
2 期
A randomised phase II study evaluating Dual inhibition of epidermal growth factor receptor (EGFR) signalling using CetUXimab and Erlotinib or dose escalated Cetuximab in patients with chemotherapy refractory KRAS wild-type metastatic colorectal cancerMetastatic colorectal cancerEGFR inhibitor induced skin toxicityCancer - Bowel - Back passage (rectum) or large bowel (colon)Skin - Other skin conditionsACTRN12611001142921Australasian Gastrointestinal Trials Group (AGITG)180
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumorslocally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defectMedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2018-000345-39-NLPfizer Inc., 235 East 42nd Street, New York, NY 10017541
已完成
2 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant TumorsNL-OMON48840Pfizer22
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumorslocally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defectMedDRA version: 20.0Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000345-39-FRPfizer Inc., 235 East 42nd Street, New York, NY 10017541
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant TumorsEUCTR2018-000345-39-ITPFIZER INC541